Literature DB >> 2839219

HLA expression in human hepatocellular carcinoma.

A C Paterson1, R Sciot, M C Kew, F Callea, G M Dusheiko, V J Desmet.   

Abstract

This study examines the expression of MHC class I and II antigens and their related invariant chains in 70 cases of human hepatocellular carcinoma (HCC), using monoclonal (Mabs) and polyclonal antibodies. In comparison with normal hepatocytes, the majority (94.3%) of HCCs show enhancement or acquisition of HLA-A, B, C in either a cytoplasmic or membranous distribution, with staining being uniformly distributed throughout the specimen. HLA-A, B, C was accompanied by beta 2-microglobulin expression in all but two cases. Although 44.9% of specimens showed HLA-DR expression, positively staining tumour cells were often sparse and heterogeneously distributed. By contrast, the invariant (I) chain, present in 47.1% of cases, was frequently intensively stained and extensive in distribution. HLA-DR staining was usually cytoplasmic although two cases showed faint membranous enhancement. In addition to HLA-DR and I-chain, two cases also showed HLA-DQ staining. Display of MHC antigens was not related to tumour differentiation or size of the lesion (resected vs. advanced tumours). It is possible that the acquisition of class I antigens by the majority of HCCs may influence tumour behaviour.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839219      PMCID: PMC2246568          DOI: 10.1038/bjc.1988.84

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  43 in total

1.  Qualitative and quantitative evaluation of indirect immunofluorescent H-2 stain on tissue sections.

Authors:  D A Saunders; T F Beals; J S Schultz
Journal:  Tissue Antigens       Date:  1979-08

2.  Detection of a common polypeptide chain in I--A and I--E sub-region immunoprecipitates.

Authors:  P P Jones; D B Murphy; D Hewgill; H O McDevitt
Journal:  Mol Immunol       Date:  1979-01       Impact factor: 4.407

Review 3.  The biological consequences of altered MHC expression on tumours.

Authors:  H Festenstein
Journal:  Br Med Bull       Date:  1987-01       Impact factor: 4.291

4.  Hepatocellular carcinoma in rural southern African blacks.

Authors:  M C Kew; E W Geddes
Journal:  Medicine (Baltimore)       Date:  1982-03       Impact factor: 1.889

5.  Anomolous expression of HLA-DR antigens on human colorectal cancer cells.

Authors:  A S Daar; S V Fuggle; A Ting; J W Fabre
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

6.  Changes in Ia-like antigen expression on malignant human cells.

Authors:  P G Natali; C De Martino; V Quaranta; A Bigotti; M A Pellegrino; S Ferrone
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

7.  Hepatitis B virus and HLA antigen display in the liver during chronic hepatitis B virus infection.

Authors:  L Montano; G C Miescher; A H Goodall; K H Wiedmann; G Janossy; H C Thomas
Journal:  Hepatology       Date:  1982 Sep-Oct       Impact factor: 17.425

8.  Immunohistochemical demonstration of H2 antigens in mouse tissue sections.

Authors:  B A Ponder; M M Wilkinson; M Wood; J H Westwood
Journal:  J Histochem Cytochem       Date:  1983-07       Impact factor: 2.479

9.  Distribution of HLA class 1 antigens in normal human tissue and in mammary cancer.

Authors:  K A Fleming; A McMichael; J A Morton; J Woods; J O McGee
Journal:  J Clin Pathol       Date:  1981-07       Impact factor: 3.411

10.  Ia-like (HLA-DR) antigens in the diagnosis of lymphoma and undifferentiated tumors.

Authors:  M E Kadin
Journal:  Arch Pathol Lab Med       Date:  1980-10       Impact factor: 5.534

View more
  17 in total

1.  HLA expression in hepatocellular carcinoma cell lines.

Authors:  A A Wadee; A Paterson; K A Coplan; S G Reddy
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

2.  Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions.

Authors:  P Sarobe; C D Pendleton; T Akatsuka; D Lau; V H Engelhard; S M Feinstone; J A Berzofsky
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

3.  HLA-DBR 1 alleles and the susceptibility of Iranian patients with breast cancer.

Authors:  A Ghaderi; A Talei; B Gharesi-Fard; S H Farjadian; A Amirzargar; M Vasei
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

4.  CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches.

Authors:  Elise Ramia; Anna Maria Chiaravalli; Farah Bou Nasser Eddine; Alessandra Tedeschi; Fausto Sessa; Roberto S Accolla; Greta Forlani
Journal:  Oncoimmunology       Date:  2018-11-26       Impact factor: 8.110

Review 5.  Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity.

Authors:  Tomoko Aoki; Naoshi Nishida; Masatoshi Kudo
Journal:  J Histochem Cytochem       Date:  2021-11-09       Impact factor: 2.479

6.  HLA class I expression in primary hepatocellular carcinoma.

Authors:  Jian Huang; Mei-Ying Cai; Da-Peng Wei
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

7.  Altered growth of a human neuroendocrine carcinoma line after transfection of a major histocompatibility complex class I gene.

Authors:  M E Sunday; K J Isselbacher; S Gattoni-Celli; C G Willett
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

8.  Expression of class I MHC molecule, HSP70 and TAP in human hepatocellular carcinoma.

Authors:  Xiao-Ling Deng; Wei Chen; Mei-Ying Cai; Da-Peng Wei
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

9.  Human hepatoma cells expressing MHC antigens display accessory cell function: dependence on LFA-1/ICAM-1 interaction.

Authors:  M Paroli; G Carloni; A Franco; G De Petrillo; E Alfani; A Perrone; V Barnaba
Journal:  Immunology       Date:  1994-06       Impact factor: 7.397

10.  Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma.

Authors:  Tomoko Aoki; Naoshi Nishida; Kazuomi Ueshima; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Akira Yamada; Keitaro Sofue; Masakatsu Tsurusaki; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-08-19       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.